Also known as: Reta
Molecular Weight
4112 Da
Half-Life
6 days
Evidence Passport
Evidence strength, status, identity, route and safety are scored separately.
Human evidence
Developing human evidence
Phase 2 evidence can show a signal without establishing approval or broad suitability.
Development status
Phase 3 development or evidence
Investigational development is not the same as approval or product suitability.
Identity match
Named compound linked
Sources are linked to the named compound; formulation and product quality remain separate questions.
Route relevance
Study protocol recorded
At least one linked source records a studied protocol; it remains study context, not an instruction.
Safety record
6 documented flags
Documented flags are visible, but absence of a listed risk would not prove safety.
No major catalogue gap is flagged, but personal suitability and product quality remain separate.
3 app-verified sources linked · Version 2026-08-31
A novel unimolecular triple agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon (GCG) receptors. Promotes satiety, enhances insulin sensitivity, increases energy expenditure via glucagon receptor activation, and significantly reduces liver fat.
These topics describe the catalogue's research index. They are not promised outcomes or personal recommendations.
TRIUMPH-2 Phase 3 Trial (2024)
Achieved 24.2% weight loss at 48 weeks with highest dose
DOI: 10.1038/s41591-024-03018-2Explore more peptides in this category
View All Metabolic Peptides →Research Disclaimer: This information is compiled from published research and is provided for educational purposes only. Peptides discussed here are classified as research chemicals in most jurisdictions and are not FDA-approved for human use unless otherwise noted. Consult a qualified healthcare provider before starting any protocol.